Recent Developments Are Changing the Narrative for GSK
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Nov 29 2025
0mins
Should l Buy GSK?
Source: Yahoo Finance
GSK's Fair Value Estimate: Analysts have slightly increased GSK's fair value estimate from £18.07 to £18.27, reflecting cautious optimism amid ongoing valuation adjustments and market conditions.
Analyst Insights: JPMorgan raised GSK's price target to 1,500 GBp while maintaining an Underweight rating, indicating concerns about potential risks despite positive valuation changes.
Regulatory and Operational Developments: GSK is investing over $350 billion in U.S. manufacturing to adapt to trade policies, and has received FDA approval for a new cancer treatment, enhancing its market position.
Legal Challenges: AnaptysBio has initiated legal action against GSK, alleging breach of a collaboration agreement, which could affect future partnerships and innovation in the oncology sector.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy GSK?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on GSK
Wall Street analysts forecast GSK stock price to fall
6 Analyst Rating
1 Buy
2 Hold
3 Sell
Moderate Sell
Current: 52.370
Low
20.15
Averages
38.72
High
55.60
Current: 52.370
Low
20.15
Averages
38.72
High
55.60
About GSK
GSK plc is a biopharma company. The Company’s segments include Commercial Operations and Research and Development. Its portfolio and pipeline are focused on developing medicines and vaccines in four core therapeutic areas, which are the areas of human health it focuses on to prevent and treat disease: respiratory, immunology and inflammation; oncology; human immunodeficiency virus (HIV), and infectious diseases. Its specialty medicines prevent and treat diseases, from HIV to respiratory diseases, immune-mediated conditions like lupus, and cancer. Its vaccine portfolio includes over 20 vaccines to protect people from diseases and infections throughout their lives. General medicines include inhaled medicines for asthma and COPD to antibiotics. It develops and commercializes preclinical antibody-drug conjugate for Metastatic castration-resistant prostate cancer. Its portfolio also includes Efimosfermin, a fibroblast growth factor 21 (FGF21) analog therapeutic in clinical development.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
GSK's Lynavoy Receives FDA Approval for Cholestatic Pruritus
- FDA Approval: GSK announced that its drug Lynavoy has received FDA approval for treating cholestatic pruritus associated with primary biliary cholangitis (PBC), marking the first approved treatment for this condition in the U.S., which is expected to significantly enhance patient quality of life.
- Successful Clinical Trials: The approval is supported by data from the GLISTEN Phase 3 trial, which demonstrated that Lynavoy led to a sustained reduction in cholestatic pruritus and itch-related sleep disturbances over 24 weeks, confirming its efficacy and safety in treatment.
- Global Collaboration Agreement: GSK has signed an agreement with Italian pharma company Alfasigma to manufacture and market Lynavoy globally, which will help accelerate the drug's market introduction and expand its market reach.
- Commitment to R&D: GSK's R&D head, Kaivan Khavandi, stated that Lynavoy is the first liver medicine from their pipeline to receive approval, underscoring the company's ongoing commitment to innovation in liver disease, with potential for further drug development in this area.
See More
Judge Blocks Major Changes to Childhood Vaccination Guidelines
- Vaccination Guidelines Blocked: A Massachusetts federal judge, Brian Murphy, issued a preliminary injunction against the HHS's plan to reduce the number of diseases covered by routine vaccinations from 17 to 11 under Secretary Robert F. Kennedy Jr., safeguarding children's health from potential risks.
- New Appointments Stayed: The judge also stayed the appointments of 13 new Advisory Committee on Immunization Practices members scheduled for June and September 2025 and January this year, indicating a strong emphasis on procedural compliance in public health governance.
- Critique of Procedural Failures: Judge Murphy criticized the Trump administration for bypassing the ACIP to alter immunization schedules, highlighting this technical procedural failure as a serious disregard for the committee's expertise, which raises concerns about the legality of the newly appointed ACIP members.
- Importance of Scientific Decision-Making: American Public Health Association CEO Georges Benjamin emphasized that the injunction underscores the necessity of employing science and qualified experts in public health decision-making, advocating for a transparent process to rebuild public trust and ensure the effectiveness of health interventions.
See More
Amgen and GSK Join TrumpRx Drug Sales Platform
- Expansion of Drug Sales: Amgen (AMGN) and GSK (GSK) are adding their medications to the TrumpRx platform, bringing the total to 54 prescription drugs available, marking a significant step in the government's push for drug affordability.
- Significant Price Discounts: Amgen plans to offer Amjevita at $299 on TrumpRx, a staggering 80% reduction from its current U.S. list price of $1,484; additionally, Aimovig and Repatha will also see around 60% discounts, greatly enhancing consumer purchasing power.
- GSK Drug Discounts: GSK's Incruse for chronic obstructive pulmonary disease will be priced at $159 on TrumpRx, reflecting a 55% discount; furthermore, other medications like Arnuity, Relenza, and Anoro will have discounts ranging from 10% to 51%, boosting market competitiveness.
- Far-reaching Policy Impact: The inclusion of Amgen and GSK not only diversifies the drug offerings on TrumpRx but also underscores the Trump administration's firm stance on drug pricing policies, aiming to enhance drug accessibility through Most Favored Nation pricing.
See More
GSK and Amgen Expand TrumpRx with New Medications - Fox Business
Prescription Drug Makers: Pharmaceutical companies are facing scrutiny for their role in the opioid crisis and the impact of their medications on public health.
Legal and Financial Consequences: Many drug manufacturers are dealing with lawsuits and financial penalties related to their marketing practices and the addictive nature of their products.
Regulatory Changes: There is a push for stricter regulations and oversight on prescription drugs to prevent misuse and ensure patient safety.
Public Health Initiatives: Efforts are being made to educate the public about the risks associated with prescription medications and to promote alternative pain management strategies.
See More
GSK Expands AREXVY Vaccine Indication for Younger Adults
- Vaccine Indication Expansion: GSK announced the expansion of AREXVY vaccine indications to adults aged 18 to 49 at increased risk for severe RSV infection, addressing a significant medical need for approximately 21 million adults in the U.S., thereby alleviating pressure on the healthcare system.
- Clinical Trial Support: The FDA's approval was supported by Phase III trial data demonstrating that the immune response in the 18 to 49 age group is non-inferior to that of adults aged 60 and older, indicating the vaccine's efficacy and safety in younger high-risk populations.
- RSV Burden Data: In the U.S., adults aged 18 to 49 experience approximately 17,000 hospitalizations, 277,000 emergency department visits, and 1.97 million outpatient visits annually, highlighting the vaccine's critical role in reducing the burden of RSV-related diseases.
- Global Market Expansion: AREXVY has been approved in 70 countries, and GSK plans to advance regulatory submissions across multiple geographies to expand vaccine availability and support long-term growth objectives.
See More
GSK's RSV Vaccine Receives FDA Approval for Expanded Age Indication
- Indication Expansion: GSK's Arexvy vaccine has received FDA approval to expand its age indication to adults aged 18 to 49 at increased risk, previously limited to those aged 60 and older, which is expected to significantly enhance market coverage and meet broader health needs.
- Epidemiological Data: In the US, adults aged 18 to 49 experience approximately 17,000 hospitalizations, 277,000 emergency department visits, and 1.97 million outpatient visits annually, indicating a high burden of RSV in this age group, and the expanded indication will help alleviate healthcare resource pressure.
- Clinical Trial Support: The FDA's approval is supported by data from a Phase IIIb trial demonstrating that the vaccine elicits a non-inferior immune response in adults aged 18 to 49 compared to those aged 60 and above, further validating the vaccine's efficacy and safety, thereby boosting market confidence.
- Global Strategic Advancement: GSK is advancing regulatory submissions for its RSV vaccine across multiple geographies to expand availability and support long-term growth objectives, demonstrating its ongoing commitment to respiratory disease prevention.
See More
GSK's Lynavoy Receives FDA Approval for Cholestatic Pruritus
- FDA Approval: GSK announced that its drug Lynavoy has received FDA approval for treating cholestatic pruritus associated with primary biliary cholangitis (PBC), marking the first approved treatment for this condition in the U.S., which is expected to significantly enhance patient quality of life.
- Successful Clinical Trials: The approval is supported by data from the GLISTEN Phase 3 trial, which demonstrated that Lynavoy led to a sustained reduction in cholestatic pruritus and itch-related sleep disturbances over 24 weeks, confirming its efficacy and safety in treatment.
- Global Collaboration Agreement: GSK has signed an agreement with Italian pharma company Alfasigma to manufacture and market Lynavoy globally, which will help accelerate the drug's market introduction and expand its market reach.
- Commitment to R&D: GSK's R&D head, Kaivan Khavandi, stated that Lynavoy is the first liver medicine from their pipeline to receive approval, underscoring the company's ongoing commitment to innovation in liver disease, with potential for further drug development in this area.
See More
Judge Blocks Major Changes to Childhood Vaccination Guidelines
- Vaccination Guidelines Blocked: A Massachusetts federal judge, Brian Murphy, issued a preliminary injunction against the HHS's plan to reduce the number of diseases covered by routine vaccinations from 17 to 11 under Secretary Robert F. Kennedy Jr., safeguarding children's health from potential risks.
- New Appointments Stayed: The judge also stayed the appointments of 13 new Advisory Committee on Immunization Practices members scheduled for June and September 2025 and January this year, indicating a strong emphasis on procedural compliance in public health governance.
- Critique of Procedural Failures: Judge Murphy criticized the Trump administration for bypassing the ACIP to alter immunization schedules, highlighting this technical procedural failure as a serious disregard for the committee's expertise, which raises concerns about the legality of the newly appointed ACIP members.
- Importance of Scientific Decision-Making: American Public Health Association CEO Georges Benjamin emphasized that the injunction underscores the necessity of employing science and qualified experts in public health decision-making, advocating for a transparent process to rebuild public trust and ensure the effectiveness of health interventions.
See More
Amgen and GSK Join TrumpRx Drug Sales Platform
- Expansion of Drug Sales: Amgen (AMGN) and GSK (GSK) are adding their medications to the TrumpRx platform, bringing the total to 54 prescription drugs available, marking a significant step in the government's push for drug affordability.
- Significant Price Discounts: Amgen plans to offer Amjevita at $299 on TrumpRx, a staggering 80% reduction from its current U.S. list price of $1,484; additionally, Aimovig and Repatha will also see around 60% discounts, greatly enhancing consumer purchasing power.
- GSK Drug Discounts: GSK's Incruse for chronic obstructive pulmonary disease will be priced at $159 on TrumpRx, reflecting a 55% discount; furthermore, other medications like Arnuity, Relenza, and Anoro will have discounts ranging from 10% to 51%, boosting market competitiveness.
- Far-reaching Policy Impact: The inclusion of Amgen and GSK not only diversifies the drug offerings on TrumpRx but also underscores the Trump administration's firm stance on drug pricing policies, aiming to enhance drug accessibility through Most Favored Nation pricing.
See More
GSK and Amgen Expand TrumpRx with New Medications - Fox Business
Prescription Drug Makers: Pharmaceutical companies are facing scrutiny for their role in the opioid crisis and the impact of their medications on public health.
Legal and Financial Consequences: Many drug manufacturers are dealing with lawsuits and financial penalties related to their marketing practices and the addictive nature of their products.
Regulatory Changes: There is a push for stricter regulations and oversight on prescription drugs to prevent misuse and ensure patient safety.
Public Health Initiatives: Efforts are being made to educate the public about the risks associated with prescription medications and to promote alternative pain management strategies.
See More
GSK Expands AREXVY Vaccine Indication for Younger Adults
- Vaccine Indication Expansion: GSK announced the expansion of AREXVY vaccine indications to adults aged 18 to 49 at increased risk for severe RSV infection, addressing a significant medical need for approximately 21 million adults in the U.S., thereby alleviating pressure on the healthcare system.
- Clinical Trial Support: The FDA's approval was supported by Phase III trial data demonstrating that the immune response in the 18 to 49 age group is non-inferior to that of adults aged 60 and older, indicating the vaccine's efficacy and safety in younger high-risk populations.
- RSV Burden Data: In the U.S., adults aged 18 to 49 experience approximately 17,000 hospitalizations, 277,000 emergency department visits, and 1.97 million outpatient visits annually, highlighting the vaccine's critical role in reducing the burden of RSV-related diseases.
- Global Market Expansion: AREXVY has been approved in 70 countries, and GSK plans to advance regulatory submissions across multiple geographies to expand vaccine availability and support long-term growth objectives.
See More
GSK's RSV Vaccine Receives FDA Approval for Expanded Age Indication
- Indication Expansion: GSK's Arexvy vaccine has received FDA approval to expand its age indication to adults aged 18 to 49 at increased risk, previously limited to those aged 60 and older, which is expected to significantly enhance market coverage and meet broader health needs.
- Epidemiological Data: In the US, adults aged 18 to 49 experience approximately 17,000 hospitalizations, 277,000 emergency department visits, and 1.97 million outpatient visits annually, indicating a high burden of RSV in this age group, and the expanded indication will help alleviate healthcare resource pressure.
- Clinical Trial Support: The FDA's approval is supported by data from a Phase IIIb trial demonstrating that the vaccine elicits a non-inferior immune response in adults aged 18 to 49 compared to those aged 60 and above, further validating the vaccine's efficacy and safety, thereby boosting market confidence.
- Global Strategic Advancement: GSK is advancing regulatory submissions for its RSV vaccine across multiple geographies to expand availability and support long-term growth objectives, demonstrating its ongoing commitment to respiratory disease prevention.
See More
